Piperacillin/tazobactam | 123683-33-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Piperacillin/tazobactam
• 英文别名: (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 123683-33-0
• 化学式: C33H39N9O12S2
• 分子量: 817.9
• InChiKey: LITBAYYWXZOHAW-XDZRHBBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.76
• 重原子数：
  56
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  313
• 氢给体数：
  4
• 氢受体数：
  15

文献信息

• [EN] PREPARATION AND USE OF PSEUDOPTEROXAZOLE AND PSEUDOPTEROSIN ANALOGS AND DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATION D'ANALOGUES ET DE DÉRIVÉS DE PSEUDOPTÉROXAZOLE ET DE PSEUDOPTÉROSINE
  申请人：NAUTILUS BIOSCIENCES CANADA INC

  公开号：WO2012139212A1

  公开（公告）日：2012-10-18

  New methods of converting pseudopterosins to pseudopteroxazoles have been developed and used to make several new non-natural pseudopteroxazole analogs. These as well as pseudopterosins and derivatives thereof and prenylated aromatic structural mimics of pseudopterosins/pseudopteroxazoles are shown to display anti-bacterial activity including that against non-replicating mycobacteria, with some exhibiting no or limited toxicity against mammalian cells.

  已经开发出将伪角藻素转化为伪角藻恶唑的新方法，并用于制造多种新的非天然伪角藻恶唑类似物。这些物质以及伪角藻素及其衍生物和伪角藻素/伪角藻恶唑的异戊二烯基芳香结构模拟物显示出抗细菌活性，包括对非复制分枝杆菌的活性，其中一些对哺乳动物细胞没有或仅有有限的毒性。
• [EN] PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS D'AJOÈNE
  申请人：UNIV DANMARKS TEKNISKE

  公开号：WO2012076016A1

  公开（公告）日：2012-06-14

  The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C=C- bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above.

  本发明涉及化合物（E,Z）-蒜烯（式1）的用途，用于治疗细菌感染。本发明的另一个方面是包含（E,Z）-蒜烯（式1）和至少一种抗生素的组合物。本发明的另一个方面涉及一种制备（E,Z）蒜烯（式1）的方法，其中内部C=C键的构象可以是E或Z或二者的混合物，所述方法包括在溶剂存在下将大蒜素（式3）与酸反应，以提供上述定义的（E,Z蒜烯）（式1）。本发明的另一个方面是通过上述描述的方法获得的（E,Z）-蒜烯（式1）。
• PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES
  申请人：Bjarnsholt Thomas

  公开号：US20140303070A1

  公开（公告）日：2014-10-09

  The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C═C— bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above.

  本发明涉及化合物（E，Z）-ajoene的公式（1），用于治疗细菌感染。本发明的另一方面是包含公式（1）的（E，Z）-ajoene和至少一种抗生素的组合物。本发明的另一方面涉及一种制备公式（1）的（E，Z）-ajoene的方法，其中内部C═C—键的构象可以是E或Z或它们的混合物，该方法包括在溶剂存在下反应公式（3）的大蒜素与酸，以提供上述定义的公式（1）的（E，Z）-ajoene。本发明的另一方面是通过上述描述的方法获得的公式1的（E，Z）-ajoene。
• Fluid component analysis system and method for glucose monitoring and control
  申请人：Optiscan Biomedical Corporation

  公开号：EP2695573A2

  公开（公告）日：2014-02-12

  An analyte detection and control system to determine and regulate the concentration of one or more analytes in a sample of bodily fluid is provided, which system comprises a control system; an analyte detector configured to measure a characteristic of at least one analyte in the sample of bodily fluid and determine a concentration of the analyte in the sample based on the measured characteristic; a fluid handling system operatively coupled to the analyte detector, said fluid handling system comprising a fluid passageway in communication with a patient through a patient end; a pump unit configured to engage the fluid handling system and draw a sample of bodily fluid from the patient periodically at draw intervals of less than 1 hour for analysis; a source of infusion fluid configured to adjust glycemic levels in the patient, said infusion fluid source in fluid communication with the fluid handling system; and a treatment dosing system in communication with the body fluid analyzer, said treatment dosing system including a treatment dosing protocol and configured to determine a recommended dose for the infusion fluid, wherein the recommended dose is determined based at least in part on one or more determinations by the body fluid analyzer of the concentration of the analyte and the treatment dosing protocol.

  提供了一种用于确定和调节体液样本中一种或多种分析物浓度的分析物检测和控制系统，该系统包括控制系统；分析物检测器，配置用于测量体液样本中至少一种分析物的特征，并根据测量的特征确定样本中分析物的浓度；流体处理系统，与分析物检测器操作性耦合，所述流体处理系统包括流体通道，通过患者端与患者通信；泵装置，配置为与流体处理系统连接，并以少于 1 小时的抽取间隔定期从患者体内抽取体液样本进行分析； 输液源，配置为调节患者体内的血糖水平，所述输液源与流体处理系统进行流体通信；以及与体液分析仪通信的治疗剂量系统，所述治疗剂量系统包括治疗剂量方案，并配置为确定输注液的推荐剂量，其中推荐剂量至少部分基于体液分析仪对分析物浓度和治疗剂量方案的一次或多次确定。
• Adjustable connector, improved fluid flow and reduced clotting risk
  申请人：OptiScan Biomedical Corporation

  公开号：US10028692B2

  公开（公告）日：2018-07-24

  Methods and systems for determining the concentration of one or more analytes from a sample such as blood or plasma are described. The systems described herein can be configured to withdraw a sample from a source of fluid, direct a first portion of the withdrawn sample to an analyte monitoring system and return a second portion of the sample. The analyte monitoring system can be connected to the fluid source via a connector that is configured to improve fluid flow and reduce blood clotting risk. These goals can be accomplished, for example, by employing coatings in or on a connector, positioning a resilient substance at or near the junction, by reducing dead space volume, by using resiliency to improve fit, by extending a portion of one connector to better mate with a portion of another connector, etc.

  本文描述了从血液或血浆等样本中确定一种或多种分析物浓度的方法和系统。所述系统可配置为从流体源提取样本，将提取样本的第一部分导入分析监测系统，并返回样本的第二部分。分析监测系统可通过连接器与流体源连接，连接器的配置可改善流体流动性并降低血液凝结风险。例如，可以通过在连接器内或连接器上使用涂层、在连接处或连接处附近放置弹性物质、减少死腔体积、利用弹性改善配合、延长一个连接器的一部分以更好地与另一个连接器的一部分配合等方式来实现这些目标。